

**Managed Care Operations Memorandum
Technology Assessment Group
MCOPS Memo # 12/2020-017**

Date: December 8, 2020

Subject: Technology Assessment Group (TAG) Coverage Decisions

To: Physical Health HealthChoices Managed Care Organizations (PH-MCOs) – Statewide

From: Laurie Rock, Director, Bureau of Managed Care Operations, Office of Medical Assistance Programs

Purpose:

To provide MCOs coverage updates on new technologies as discussed in regular TAG meetings.

Background:

The TAG workgroup meets quarterly on the 2nd Friday of February, May, August and November to discuss issues and evidence-based research pertaining to evolving new technologies and previously reviewed technologies or services that were determined to be covered only through a program exception request. During the TAG meetings, decisions are made as to whether or not certain technologies or services will be covered under the MA Program and the option under which it will be covered. TAG's coverage options are as follows:

- **Option # 1: Approved- will be added to the Fee Schedule**
- **Option # 2: Approved as Medically Effective under specific clinical condition- will require Program Exception**
- **Option # 3: Approved with (or denied due to) Limited/Minimal Evidence of Effectiveness- will require Program Exception**
- **Option # 4: Denied- Experimental/Investigational**

Discussion:

Below are the updated list of codes/descriptions discussed at the August 5, 2020, TAG Meeting and the decisions that were made:

HCPCS/CPT Code	Description	Decision
reSET & reSET-O	Digital therapy platform used to increase engagement with individuals struggling with addiction treatment, Substance Use Disorder (SUD) or Opioid Use Disorder (OUD)	New in 2020: reviewed in meeting. Option #3
81221	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; known familial variants	Re-reviewed at this meeting. Option #1
81222	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; duplication/deletion variants	Re-reviewed at this meeting. Option #1
81223	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; full gene sequence	Re-reviewed at this meeting. Option #1

This memo is not intended to replace any existing Prior Authorization Review Processes currently being utilized; it is for informational/internal purposes only.

Next Steps:

N/A

Obsolete:

N/A

Attachment:

N/A